The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
This looks like the best opportunity I have seen in a long time.
Tiny market cap.
Patented, owned tech.
A global market which is never going to go away.
A partnership with a $4B NASDAQ company with an "in" to global players in that market.
There is nothing not to like about this IMO.
Wow!! Four months ago!
Stop spamming the board. I know that's what you do on your brief stays on every board you visit, but maybe a change of habit would be nice.
Today's price movement is encouraging. Let's leave it at that and see what develops.
Have taken a big loss here today.
I should have listened to myself when the recent update RNS spoke of a potential sale and leaseback - the financing option of last resort.
Thought I could do a quick trade and get out on the next vaguely positive RNS trumpeted by the usual Twitter pumpers, but today's news put an end to that notion. Going from talk of a sale and leaseback to engaging restructuring specialists is yet another downward spiral.
If I hadn't been in here already at 7am today I might have seen a chance for a quick dead cat bounce day trade today, but no other sort of trade or investment in this company looks attractive right now. They have no money and the bank has them by the short and curlies.
Looks like the bank saw £3M come in from the placing and saw their opportunity to guarantee recouping at least half of their £6M loan.
Skeletor, the contracted revenue of £60M last year was as at 11th April 2022. This is 23rd March 2023, so it's not an exact comparison.
Also, much of the contracted revenue as at 11th April 2022 will have come in before the Russian invasion of Ukraine, before inflation became rampant and before fears of a global recession kicked in.
It's perfectly possible that BOOM will match or beat last year's revenue total as they are two thirds of the way there already in terms of contracted revenue les than three months in to the year.
Also, at 11th April last year, when £60M contracted revenue for the year was in place, the SP was 1965p, more than five times higher than it is now. I think therefore it is reasonable to assume there is a fair degree of upside from here after today's positive RNS.
we had an RNS where the CEO alluded to chemotherapy without side effects. The SP rose sharply after this.
Towards the end of February the company held a science day at which a comparative table of its modified drug vs standard dox disclosed side a wide range of side effects being experienced by patients receiving the modified drug.
Since that table was shared on Twitter two weekends ago, the SP has fallen sharply.
Even if the company were to achieve a modified version of the dug which were, say, markedly to reduce just one side effect (cardiotoxicity) in the treatment of one form of cancer, that would be a significant achievement and, I would think, commercially lucrative.
However, by raising expectations of a silver bullet the company has set itself up for a fall, whereby results which are good are not going to be deemed good enough by the markets, hence the company's SP now being LOWER than before the initial January RNS.
in my opinion is that there was an RNS in January in which the CEO stated that AVCT is working towards chemotherapy without side effects and cited very positive outcomes from the Phase 1a data for the current clinical trial.
More detailed data was published last week on the science day, including a table comparing side effects after two cycles of AVCT's modified drug compared with after I think seven cycles of standard dox.
That table listed quite a lot of side effects having shown themselves for AVCT's drug. Not in as high a % of patients as with standard dox, but then it's been fewer cycles.
I am neither a chemist or an oncologist, but the table in question did not to this layman indicate any kind of silver bullet. More explanation from the company of what the figures mean would help retail investors form a clearer view of how things are progressing. I sold my shares yesterday at 150p as the market in that last 12 months has been very difficult and I am being a bit more cautious than previously. GLA.
Is less than 1 x 2022 revenues, for a profitable, growing company is a sector where takeovers happened within the past two years at 5-7 x revenues. A company with a growing cash pile and negligible risk of any cash raise being required in the foreseeable future. A company where a director has bought shares in £10k -£20k tranches umpteen times over the last year.
Who knows where the bottom is for the SP as it is completely disconnected from company performance or sector valuation norms.
What is abundantly clear IMO is that the company is already hugely undervalued.
I agree that these results are very good. £44 million advertising revenue pre-booked for the year, compared to £45 million in the equivalent January trading update last year. Considering the loss of morbid and the cost of living crisis that has engulfed the developed world since then, this shows growth compared to the much more favourable background in which BOOM was operating a year ago. That's really impressive IMO.
BOOM has lost 80%+ of its market cap since early last year despite increasing revenue and profit during that period in the face of major economic headwinds. Surely such a disconnect between SP performance and company performance is not sustainable and value must win out here.
Another 26 wells like this one and that'll be as many barrels of oil as Paul Haywood told Jeremy Naylor of IG were gushing daily on a 1/4 inch choke from BLOE's significantly scaled back debut well at West Rustavi back in 2019.
Fingers crossed.
down more than 80% since April / May this year.
What has changed?
The company lost a big podcast.
Advertising revs have slowed across the board.
The company has dealt pretty well with the first matter - it continues to grow the downloads of its other podcasts.
The latter factor will reverse as economic conditions steady and improve.
It's hard to guess where the short term bottom might be. That probably depends on the next quarterly figures and how they shape up.
I am convinced, though, that for anyone with some patience this is already a hell of a bargain.
Yawn
The RNS this morning is a double-edged sword. On the plus side, it reaffirms revenue growth and trading within market expectations. On the other hand, it doesn't in my view dispel uncertainty over Azerion. It confirms there is no litigation between the parties, but does not deny that there may not be a meeting of minds between the two parties as to Azerion's entitlement or otherwise to withdraw from their current contractual arrangements.
There couldn't really be more of a buy signal here than Ursula von der Leyen's comments on rare earths and the EU's now stated priority focus on securing supply lines and reserves of RRE's.
MKA is a sitting duck here.
Aaquaverse being out (or nearly out) is the best news BOOM holders have had in months. Aaquaverse's fire sale of their shares has had nothing to do with the company's fundamentals but has utterly trashed the market cap. Maybe now the company will start to be valued according to its fundamentals again, which would see a MUCH higher share price than that which we have today.
the selling will stop and this company's market cap will start to return to where it shoulf be. We know a major shareholder has been selling for reasons unrelated to the compsny fundamentals. This has happened at a time when rev growth is likely under a bit of pressure due to the risk of recession and associated pressure on advertising income. All this will pass. We don't know when though and that's why we don't know where the SP will bottom out. Wherever it bottoms out it will be at massive undervalue in the medium term imo.
The Candy v Bonnier court case is good news in a very important sense.
It means that Candy and Aaqua's share interests in BOOM are now very unlikely to form a bloc as regards future takeover activity in the company.
A future takeover bid from a global business of unimpeachable repute is more likely imo now as bidders know they will have a more realistic chance of success. Hopefully any bid from one of the big players in the market would be at a more realistic price than the previous low ball offer from All Active Capital.
Back at the level this immediately fell to after FDA knock back last year. Should rise nicely in the run up to fresh FDA decision due in Sept, especially as resubmission deals with known queries which company has talked through with FDA.
We know the tech works.
GLA.
astro, don't beat yourself up about it. You would have been very brave to average down when there was the cost of 50km of road works hanging over the company. 5km of road works, per this week's rns, is obviously much less scary from a cost perspective, but at the time you might have averaged down, you didn't know that the scope of the required road works would be revised downwards by 90%.
that there won't be a bid from any group involving AAQUA any time soon. Ideally AAQUA will dispose of enough stock to unrelated parties for the result to be that the AAQUA block no longer holds more than 25% and cannot therefore block a third party bid. That would help to pave the way for a future bid at a realistic level from one of the tech giants, which would be much preferable imo.